Navigation Links
ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met,Inhibitor, for Oral Presentation at ASCO

are presented or published. Following is a list of the abstracts related to ARQ 197 and ARQ 501 that have been accepted at the ASCO and AACR meetings.

ASCO Abstracts

For oral presentation

-- A Phase 1 dose escalation study of ARQ 197, a selective inhibitor of the c-Met receptor in patients with metastatic solid tumors

For publication in ASCO proceedings

-- A Phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma

-- A Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS)

AACR Abstracts

-- Pharmacokinetics of a novel PGA-ARQ 501 conjugate in mouse xenografts

-- Mass balance and characterization of the Metabolites of ARQ 501 ((beta)-lapachone), a checkpoint pathway activator in clinical development

-- Pharmacodynamic biomarkers for checkpoint pathway activator ARQ501 in a human colon xenograft model

-- Selective induction of necrotic cell death in cancer cells by (beta)-lapachone through activation of DNA damage response pathway

-- Evaluation of biomarkers for HGFR/c-Met inhibitor ARQ 197 in a human xenograft model

-- Functional chemogenomics approach to identify checkpoint pathway activators against cancer

-- Selective killing of cancer cells by activation of human checkpoint kinase 2

-- ARQ 197, a highly selective small molecule inhibitor of c-Met, inhibits invasive and metastatic growth of cancer cells

-- ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells

-- Broad spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met Inhibitor, in multiple xenograft models

-- Anti-metastatic activity of ARQ 197, a highly selective oral small molecule inhibitor of c-Met,
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:9/23/2014)... 2014 FDNA présentera ... série de démonstrations personnelles   FDNA® ... de l,analyse de la dysmorphologie assistée par ... lors de la réunion ASHG 2014, qui se ... , en Californie. FDNA présentera la dernière ...
(Date:9/23/2014)... , September 23, 2014 ... l,automobile, la santé, le ferroviaire ou encore ... connectées, donneront progressivement accès à leurs données. ... nombreux capteurs installés au cœur des voitures, ... plusieurs dizaines de milliards le nombre de ...
(Date:9/23/2014)... ORLANDO, Fla. and DUBLIN ... Inc. (OTC-BB: TNIB) ("we" or the "Company"), a ... innovative therapies for autoimmune diseases in emerging nations, ... has approved our common stock for DTC,s Deposit ... Fast Automated Securities Transfer Service ("FAST") transfer agent ...
Breaking Medicine Technology:FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Altran transforme le big data du monde industriel en nouveau business 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4
... (NASDAQ: SIAL ) today announced that its ... ), is introducing a novel CHOZN® GS-/- Zinc Finger ... for use in the production of biopharmaceuticals, the new ... glutamine synthetase (GS) knockout CHO cell line proven to ...
... LAS VEGAS, Oct. 26, 2011 Clinical Research Management, ... basic and applied research, clinical trials, and regulatory support, ... Boyer, Ph.D., will co-present a panel titled Battle ... the MAGI West Clinical Research Conference, October 23-26, 2011 ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4ClinicalRM to Co-Present Regulatory Compliance Panel at MAGI 2
(Date:9/23/2014)... Sept. 23, 2014 (HealthDay News) -- Few ... also undergo behavioral therapy, and the rates vary ... new study finds. Medication alone can manage ... do better if they also receive behavioral therapy ... researchers analyzed data in more than 1,500 counties ...
(Date:9/23/2014)... an exercise DVD that adds short breaks of physical ... found it had a high level of popularity with ... overly sedentary educational programs. , Called "Brain Breaks," the ... Program of the Linus Pauling Institute at Oregon State ... children in 5-7 minute segments of physical activity, demonstrated ...
(Date:9/23/2014)... showing the benefits of preventing a reduction in ... was released today by the American College of ... Save the Medicaid Primary Care Pay Parity Program: ... Life-Saving Primary Care Will Expire," explains why it ... internists and pediatricians (and their related subspecialists), family ...
(Date:9/23/2014)... September 23, 2014 Vancouver Electrician Contractors, ... be offering commercial electrical services in Vancouver, BC. The ... whether it is a small maintenance project or a ... solution package to meet the needs of the individual ... services will be of an affordable price. As a ...
(Date:9/23/2014)... Dallas, Texas (PRWEB) September 23, 2014 ... market for allergic rhinitis (AR) is highly ... having different SIT formulations available, under different ... crossover between markets. Europe has the most ... immunotherapy (SLIT), and allergen immunotherapy tablets (AITs) ...
Breaking Medicine News(10 mins):Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4
... The new ... on the brand’s two-stage product program. , ... (Vocus) March 12, 2010 -- Metabolife launched Metabolife® Green Tea + Vitamin D3 ... and wellness. The new product, an extension of the stage-one product portfolio, builds on the ...
... ... ... U.S. HealthWorks , one of the nation’s largest operators of outpatient health care centers ... will host its 2nd healthcare symposium for U.S. HealthWorks Medical Group physicians and affiliated clinicians ...
... O.N.E., One Natural Experience debuts O.N.E. Active, an innovative ... extra mile.  O.N.E. Active provides the same all natural health ... O.N.E. Coconut Water -- but with the addition of ginkgo ... of sharpening the mind while engaging in sports or any ...
... Campaign to Generate One Million Emails to Congress , ... , , ... ... DALLAS , March 12 ...
... shift in daylight, experts say , , FRIDAY, March 12 (HealthDay ... time this Sunday because it starts to stay light longer, even ... , However, that shift may not be such a welcome change ... occurs in the fall and winter and is caused, at least ...
... heart failure by 20%. Silke Schmidt et al. present ... Deutsches rzteblatt International ( Dtsch Arztebl Int ... wide variety of clinical applications of electronic transfer of ... such as heart rate, blood pressure and oxygen saturation, ...
Cached Medicine News:Health News:Metabolife's New Green Tea + Vitamin D3 Helps Promote Bone Health and Supports Weight Management 2Health News:U.S. HealthWorks Hosts Healthcare Symposium 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 2Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 3Health News:All in O.N.E. ... O.N.E.(TM) Natural Experience Introduces O.N.E. Active(TM), a New Natural Sports Drink That Combines the Super Hydration Power of Coconut Water With Energizing Herbs and Minerals to Provide the Ultimate MIND/BODY Experience 4Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 2Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 3Health News:Think Tank & Radio Network Encourage Massive Resistance to ObamaCare 4Health News:Daylight Savings: Not a Bright Time for All 2Health News:Daylight Savings: Not a Bright Time for All 3
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... 30° Prism are designed for ... recommended for tractional retinal detachments ... retinal detachment. They can be ... other midperipheral laser applications. Direct ...
... High-Mag 1.5x is specifically designed ... in macular hole surgery, optic ... membrane removal, traditional macular edema ... magnification. This lens was developed ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
Medicine Products: